Jul 28, 2024, 15:37
Joshua D. Palmer: TURBO-NSCLC study looking at TKI alone or combination with SRS for brain metastasis
Joshua D. Palmer, Radiation Oncologist and Associate Professor at The Ohio State University Wexner Medical Center, shared a post on X about a recent paper by
“Check out the TURBO-NSCLC study looking at Up-Front next generation Tyrosine kinase inhibitors (TKI) alone or combination with Stereotactic radiosurgery (SRS) for brain metastasis. We found that combination with SRS had better local control and time to progression especially for lesions >1cm.”
Tyrosine Kinase Inhibitors with and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC) published in ASCO Publications.
Authors:
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 10:59
Nov 13, 2024, 10:54
Nov 13, 2024, 10:45
Nov 13, 2024, 09:39